The Janssen Medical Cloud section ‘Janssen in rheumatology’, is intended for physicians working in the field of rheumatology, more
specifically for the disease of Psoriatic Arthritis. As a loyal partner, we offer you, as a physician, useful information and services within this

On our website you will find information about studies, patient materials that you can download, medical education programs, a conference
agenda and so much more.


Rheumatology in 2030: a lively conversation between two Benelux key opion leaders in rheumatology.
Check it out and click here below to get a short flavour of the podcasts.



Rheumatology in 2030. A lively conversation between two Benelux key opinion leaders in rheumatology.

Rheumatology in 2030 part 1:

Technical innovations and improvements benefiting both patients and medical specialists

When two distinguished Benelux rheumatologists look ahead to the evolution of their specialty in
the next ten years, their optimism is striking. They emphasize the technical innovations and
improvements that have recently been implemented, which benefit both the patient and the
medical specialist, also on the administrative platform. In a patient-oriented context they will take
advantage of digital means, and they can also communicate and share the best expertise in an
optimal international network. They will also learn a lot more of what’s really happening in the
earliest stages of the disease.

Listen to the full podcast >

Rheumatology in 2030 part 2:

Technical innovations and improvements benefiting both patients and medical specialists

The role of the rheumatologist is shifting towards that of the expert or the coach in the context of a personalized medicine where shared decisions are taken, in order to find the best treatment. The rheumatology section becomes more and more an outpatient clinic. In an integral network also the voice of the patient will be heard. Communicating in a broader field of work, the rheumatologist gets closer to primary care, aware of healthy food and lifestyle, giving general advice and guiding the patients.

Listen to the full podcast >



20 November 2020

European Commission has approved TREMFYA® (guselkumab) for the treatment of adult patients with active psoriatic arthritis (PsA) who have had an inadequate
response or who have been intolerant to a prior disease-modifying antirheumatic drug (DMARD) therapy.

16 October 2020

Janssen Receives CHMP Positive Opinion for Expanded Use of TREMFYA® (guselkumab) in the Treatment of Active Psoriatic Arthritis (PsA) in the European Union

14 July 2020

TREMFYA® (guselkumab) Approved by U.S. Food and Drug Administration as the First Selective Interleukin (IL)-23 Inhibitor for Active Psoriatic Arthritis.

20 October 2019

Janssen Seeks to Expand Use of TREMFYA® (guselkumab) in the Treatment of Adults with Active Psoriatic Arthritis.





9-11 September 2021


Michel Delforge and Mohamad Mohty





CP-226786 - 21-apr-2021